MLSS logo

Milestone Scientific Inc. Stock Price

NYSEAM:MLSS Community·US$36.7m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

MLSS Share Price Performance

US$0.42
-0.49 (-54.26%)
US$1.00
Fair Value
US$0.42
-0.49 (-54.26%)
58.5% undervalued intrinsic discount
US$1.00
Fair Value
Price US$0.42
AnalystConsensusTarget US$1.00
AnalystLowTarget US$1.25
AnalystHighTarget US$2.00

MLSS Community Narratives

·
Fair Value US$1 58.5% undervalued intrinsic discount

Global Expansion And Minimally Invasive Care Will Shape Future Progress

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$1.25 66.8% undervalued intrinsic discount

Healthcare Cost Pressures Will Limit Adoption Yet Progress Will Emerge

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$2 79.2% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Drive Minimally Invasive Procedures

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$1.25
66.8% undervalued intrinsic discount
Profit Margin
12.49%
Future PE
78.48x
Price in 2028
US$1.54

Trending Discussion

Updated Narratives

MLSS logo

MLSS: Medical Adoption And New Capital Raise Will Support Future Upside

Fair Value: US$1 58.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MLSS logo

Healthcare Cost Pressures Will Limit Adoption Yet Progress Will Emerge

Fair Value: US$1.25 66.8% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MLSS logo

Aging Populations And Emerging Markets Will Drive Minimally Invasive Procedures

Fair Value: US$2 79.2% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with low risk.

3 Risks
2 Rewards

Milestone Scientific Inc. Key Details

US$8.9m

Revenue

US$2.6m

Cost of Revenue

US$6.3m

Gross Profit

US$10.9m

Other Expenses

-US$4.6m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.052
71.03%
-51.30%
35.0%
View Full Analysis

About MLSS

Founded
1989
Employees
15
CEO
Eric Hines
WebsiteView website
www.milestonescientific.com

Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally. It operates through Dental and Medical segments. The company provides The Wand, a single use disposable handpiece device for dental procedures that require local anesthetic under the CompuDent and STA Single Tooth Anesthesia System names. It also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, the company provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Further, it offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.

Recent MLSS News & Updates

Narrative Update May 27

MLSS: Medical Adoption And New Capital Raise Will Support Future Upside

Analysts have adjusted their price target on Milestone Scientific to $1.00, supported by updated assumptions that include a slightly lower discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue of US$9.8 million to US$10.2 million, tied to commercial adoption in both dental and medical segments (Corporate Guidance).

Recent updates

No updates